Literature DB >> 31315844

Metastatic prostate cancer presenting as tumour-induced osteomalacia.

Awo Akosua K Layman1, Shivam Joshi2, Sanjeev Shah3,4.   

Abstract

Tumour-induced osteomalacia (TIO), or oncogenic osteomalacia, is a paraneoplastic syndrome marked by hypophosphataemia, renal phosphate wasting, bone pain, weakness, and fractures. The syndrome has been reported with both benign and malignant tumours including parotid gland basal cell tumours, thyroid carcinomas, colon adenocarcinomas, and prostate cancer. Often, the syndrome is marked by an insidious course during which patients present with generalised bony pain and weakness, which do not resolve until the underlying tumour is identified and treated. We present a case of a patient with Parkinson's disease whose subacute weakness, lower extremity paresis, and renal phosphate wasting led to the synchronous diagnosis of metastatic prostate adenocarcinoma and TIO. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  calcium and bone; prostate

Mesh:

Substances:

Year:  2019        PMID: 31315844      PMCID: PMC6663299          DOI: 10.1136/bcr-2019-229434

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  31 in total

1.  [Rickets following bone tumor].

Authors:  A PRADER; R ILLIG; E UEHLINGER; G STALDER
Journal:  Helv Paediatr Acta       Date:  1959-12

2.  Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years.

Authors:  R A McCANCE
Journal:  Q J Med       Date:  1947-01

3.  Tumor-induced osteomalacia.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Expert Rev Endocrinol Metab       Date:  2009-09-01

4.  Phosphorus content of popular beverages.

Authors:  Melissa Moser; Karen White; Bobbie Henry; Susan Oh; Edgar R Miller; Cheryl A Anderson; Jonathan Benjamin; Jeanne Charleston; Lawrence J Appel; Alex R Chang
Journal:  Am J Kidney Dis       Date:  2015-04-08       Impact factor: 8.860

5.  Mineral metabolism abnormalities in patients with prostate cancer: a systematic case controlled study.

Authors:  Francesco Minisola; Cristiana Cipriani; Luciano Colangelo; Mirella Cilli; Alessandro Sciarra; Magnus Von Heland; Luciano Nieddu; Emanuela Anastasi; Roberto Pascone; Valeria Fassino; Daniele Diacinti; Flavia Longo; Salvatore Minisola; Jessica Pepe
Journal:  Endocrine       Date:  2017-06-28       Impact factor: 3.633

Review 6.  Oncogenic osteomalacia associated with metastatic prostate carcinoma: case report and review of the literature.

Authors:  C T McMurtry; M Godschalk; H H Malluche; Z Geng; R A Adler
Journal:  J Am Geriatr Soc       Date:  1993-09       Impact factor: 5.562

7.  Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4.

Authors:  Jyothsna Gattineni; Priyatharshini Alphonse; Qiuyu Zhang; Nisha Mathews; Carlton M Bates; Michel Baum
Journal:  Am J Physiol Renal Physiol       Date:  2013-11-20

8.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Makoto Kakitani; Yuji Yamazaki; Hisashi Hasegawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Kazuma Tomizuka; Takeyoshi Yamashita
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

9.  Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.

Authors:  Itsuro Endo; Seiji Fukumoto; Keiichi Ozono; Noriyuki Namba; Hiroyuki Tanaka; Daisuke Inoue; Masanori Minagawa; Toshitsugu Sugimoto; Mika Yamauchi; Toshimi Michigami; Toshio Matsumoto
Journal:  Bone       Date:  2008-03-05       Impact factor: 4.398

10.  Tumor induced osteomalacia secondary to anaplastic thyroid carcinoma: A case report and review of the literature.

Authors:  Ejigayehu G Abate; Victor Bernet; Cherise Cortese; Hillary W Garner
Journal:  Bone Rep       Date:  2016-02-17
View more
  1 in total

1.  Exploring the Pharmacological Mechanisms of Xihuang Pills Against Prostate Cancer via Integrating Network Pharmacology and Experimental Validation In Vitro and In Vivo.

Authors:  Yongrong Wu; Xujun You; Qunfang Lin; Wei Xiong; Yinmei Guo; Zhen Huang; Xinjun Dai; Zhengjia Chen; Si Mei; Yan Long; Xuefei Tian; Qing Zhou
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.